There are currently 17 active clinical trials seeking participants for Depressive Disorder, Major research studies. The states with the highest number of trials for Depressive Disorder, Major participants are California, Florida, Texas and New York.
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05455684
Recruiting
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2024
Locations: SW Biomedical Research LLC, Tucson, Arizona +118 locations
Conditions: Depressive Disorder, Major, Anhedonia
Register for Updates
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
NCT05518149
Recruiting
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI]) in all participants with major depressive disorder (MDD).
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2024
Locations: University of Alabama at Birmingham - The Kirklin Clinic, Birmingham, Alabama +162 locations
Conditions: Depressive Disorder, Major
Register for Updates
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05550532
Recruiting
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate to severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +119 locations
Conditions: Depressive Disorder, Major, Anhedonia
Register for Updates
Psilocybin for Major Depressive Disorder (MDD)
NCT06308653
Recruiting
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Preferred Research Partners, Inc., Little Rock, Arkansas +9 locations
Conditions: Depressive Disorder, Major
Register for Updates
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
NCT05841030
Recruiting
The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with anhedonia with inadequate response to their current antidepressant treatments and treated according to the standard of care treatment.
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
06/17/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +60 locations
Conditions: Depressive Disorder, Major
Register for Updates
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
NCT06280235
Recruiting
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression. Participants continue their standard therapy throughout the study. Participants are put into 4 groups by chance. 3 of the 4 groups take different doses of BI 1569912. 1 group takes placebo. Placebo tablets looks like BI 1569912 but... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/31/2024
Locations: Southwest Biomedical Research, LLC, Tucson, Arizona +18 locations
Conditions: Depressive Disorder, Major
Register for Updates
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
NCT05915013
Recruiting
The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
04/03/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Depressive Disorder, Major, Bipolar Disorder, Post Traumatic Stress Disorder
Register for Updates
Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
NCT05708222
Recruiting
The objective of this study is to collect data to finalize the development of MEB-001 software as a medical device. The data collected in this study will be used to develop MEB-001 machine learning algorithms by training the algorithms to match the patient's demographic and clinical information, and the objective physiological signals (i.e., electroencephalogram (EEG) and electrocardiogram (ECG)) recorded during PSG with the diagnosis of cMDE performed through the MINI neuropsychiatric evaluatio... Read More
Gender:
All
Ages:
Between 22 years and 75 years
Trial Updated:
04/02/2024
Locations: Medbridge Healthcare, Bradenton, Florida +12 locations
Conditions: Depressive Episode, Depression, Depressive Disorder, Depressive Disorder, Major, Depression Mild
Register for Updates
Brain Network Dynamics of Depression During Esketamine Treatment
NCT06012916
Recruiting
This is a monocentric, observational clinical trial investigating the effect of Esketamine on brain network activity and a belief updating task in people with depression. We investigate the immediate and the long-term effect (approx. 8 weeks) of Esketamine on EEG signals, pupillometry and belief updating and the relation of those effects on depressive symptomatology.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
02/27/2024
Locations: Carolina Center for Neurostimulation, Chapel Hill, North Carolina
Conditions: Depressive Disorder, Major
Register for Updates
Modulating Repetitive Negative Thinking Related Brain Networks in Young Adults With Depression
NCT06219681
Recruiting
In this project, we use real-time fMRI neurofeedback (rtfMRI-nf) to causally relate dysfunction of right anterior insula (rAI) and right superior temporal sulcus (rSTS) connectivity with the intensity of repetitive negative thinking (RNT). We hypothesize that rtfMRI-nf reducing rAI-rSTS connectivity would reduce RNT. We propose a randomized double-blind, sham-controlled trial of rtfMRI-nf with 110 young adults (n=55/arm) with major depressive disorder (MDD) and high trait-RNT levels.
Gender:
All
Ages:
Between 18 years and 35 years
Trial Updated:
01/12/2024
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Depressive Disorder, Major
Register for Updates
Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness
NCT05491538
Recruiting
Many individuals with serious mental illness have difficulty accurately interpreting interpersonal cues and effectively engaging in social exchanges. Difficulties related to the interpersonal aspects of work can lead to isolation, poor productivity, and job loss. The goals of this study are to: 1) adapt an evidence-based social cognitive skills intervention for work settings and use with Veterans, 2) examine the acceptability of the work focused skills training intervention, 3) assess the feasib... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
Conditions: Schizophrenia, Bipolar Disorder, Depressive Disorder, Major, Stress Disorder, Post-Traumatic
Register for Updates
Individualized Functional Connectivity Targeting in aiTBS for Depression
NCT05680727
Recruiting
The goal of this clinical trial is to estimate the importance of neuroimaging in accelerated intermittent theta burst stimulation (aiTBS) for depression. Participants will receive aiTBS treatment, but they will not know if their treatment spot was found with neuroimaging or head measurements.
Gender:
All
Ages:
Between 22 years and 80 years
Trial Updated:
11/29/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Depressive Disorder, Major, Depression, Mood Disorders, Mental Disorder, Psychiatric Disorder
Register for Updates